Revelation Biosciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
48.0%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$5.00next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly14.1MTarget: Sufficient capital to fund operations through Q1 2027
Quarterly Net Loss Quarterly-3MTarget: Minimize cash burn through disciplined R&D and G&A spending
Quarterly Operating Cash Outflow Quarterly-3.2MTarget: Maintain controlled operational burn rate
Watch Items
- Initiation of Pivotal Phase 2/3 Gemini AKI Clinical StudyTrigger: Targeted start in Q4 2026Action: Monitor clinical trial infrastructure setup, site activation, and patient enrollment milestones.
- Nasdaq Minimum Bid Price ComplianceTrigger: Stock price consistently trading below $1.00Action: Track potential implementation of the board's authorized reverse stock split (ranging from 1-for-2 up to 1-for-250) to maintain listing.
- Going Concern Status and Capital RunwayTrigger: Cash runway projected to expire in Q1 2027Action: Evaluate opportunities for public/private equity offerings, debt financing, or strategic partnerships to extend the runway.
Research as of 20 Jun 2026